958228-07-4

Upstream product

• 7170-01-6 3-methyl-1H-[1,2,4]triazole 
• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 
• 7170-01-6 5-methyl-1H-1,2,4-triazole 

Downstream Products

• 958228-10-9 tert-butyl (E)-5-chloro-2-[1-[3-methoxy-4-(3-methyl[1,2,4]triazol-1-yl)phenyl]methylidene]valerate 
• 958227-84-4 (Z)-4-[(S)-1-(4-fluorophenyl)ethyl]-2-[1-[3-methoxy-4-(3-methyl[1,2,4]triazol-1-yl)phenyl]methylidene]-6,6-dimethylmorpholin-3-one 
• 958227-87-7 (Z)-4-[(S)-chroman-4-yl]-2-[1-[3-methoxy-4-(3-methyl[1,2,4]triazol-1-yl)phenyl]methylidene]-6,6-dimethylmorpholin-3-one 
• 958228-01-8 (E)-(3S,8aS)-3-(3,4-difluorophenyl)-6-[3-methoxy-4-(3-methyl[1,2,4]triazol-1-yl)benzylidene]hexahydroindolizin-5-one 
• 958228-03-0 (E)-(6S,9aR)-6-(4-fluorophenyl)-3-{1-[3-methoxy-4-(3-methyl[1,2,4]triazol-1-yl)phenyl]methylidene}octahydroquinolizin-4-one 

Relevant academic research and scientific papers

HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE

Disclosed is a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof. Also disclosed is a use of the compound or salt as a pharmaceutical product. (In the formula, Ar1 represents a triazolyl group or the l

TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS

Compounds of formula I: Selectively attenuate production of Aβ(1-42) and hence find use in treatment or prevention of diseases associated with deposition of Aβ in the brain, in particular Alzheimer's disease.